二十碳五烯酸乙酯对既往心肌梗死患者心血管事件与死亡的影响
REDUCE-IT 试验的事后分析纳入 3,693 例既往心肌梗死患者,比较在他汀治疗基础上加用二十碳五烯酸乙酯(IPE)与安慰剂的疗效。结果显示 IPE 显著降低主要终点(26.1% 降至 20.2%,HR 0.74,95%CI 0.65-0.85,P=0.00001)及关键次要终点(18.0% 降至 13.3%,HR 0.71,95%CI 0.61-0.84,P=0.00006),但房颤略有增加。
要点
- 关键次要终点(心血管死亡、心梗或卒中)HR 0.71,95%CI 0.61-0.84。
- 总缺血事件相对风险降低 35%,但房颤发生率略有增加。
核心结论
- 在 REDUCE-IT 中,既往心肌梗死患者接受 IPE 治疗后缺血事件(包括心血管死亡)的相对和绝对风险均显著降低。
研究设计与样本
- REDUCE-IT 为双盲随机对照试验,共随机分配 8,179 例接受他汀治疗、低密度脂蛋白胆固醇控制且甘油三酯中度升高的患者至 IPE 或安慰剂组。
- 本分析为针对其中 3,693 例有既往心肌梗死病史患者的事后分析。
主要发现
- 主要终点(心血管死亡、心肌梗死、卒中、冠状动脉血运重建或不稳定型心绞痛住院)从安慰剂组的 26.1% 降至 IPE 组的 20.2%,HR 0.74(95%CI 0.65-0.85,P=0.00001)。
- 关键次要终点(心血管死亡、心肌梗死或卒中)从 18.0% 降至 13.3%,HR 0.71(95%CI 0.61-0.84,P=0.00006)。
- 总缺血事件相对风险降低 35%(P=0.0000001),心肌梗死减少 34%(P=0.00009),心血管死亡减少 30%(P=0.01),全因死亡率降低 20%(P=0.054)。
- 心脏性猝死和心脏骤停分别显著减少 40% 和 56%。
- 房颤略有增加。
临床怎么用
- 对于既往心肌梗死且已接受他汀治疗、低密度脂蛋白胆固醇控制而甘油三酯中度升高的患者,可考虑加用 IPE 以降低缺血事件风险。
- 临床决策时应权衡缺血事件减少的获益与房颤风险略有增加的可能。
局限性
- 本分析为 REDUCE-IT 的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: REDUCE-IT was a double-blind trial that randomized 8,179 statin-treated patients with controlled low-density lipoprotein cholesterol and moderately elevated triglycerides to icosapent ethyl (IPE) or placebo. There was a significant reduction in the primary endpoint, including death from cardiovascular (CV) causes. The specific impact of IPE among patients with prior myocardial infarction (MI) was unknown. OBJECTIVES: Our goal was to examine the benefit of IPE on ischemic events among patients with prior MI in REDUCE-IT. METHODS: We performed post hoc analyses of patients with prior MI. The primary endpoint was CV death, MI, stroke, coronary revascularization, or hospitalization for unstable angina. The key secondary endpoint was CV death, MI, or stroke. RESULTS: A total of 3,693 patients had a history of prior MI. The primary endpoint was reduced from 26.1% to 20.2% with IPE vs placebo; HR: 0.74 (95% CI: 0.65-0.85; P = 0.00001). The key secondary endpoint was reduced from 18.0% to 13.3%; HR: 0.71 (95% CI: 0.61-0.84; P = 0.00006). There was also a significant 35% relative risk reduction in total ischemic events (P = 0.0000001), a 34% reduction in MI (P = 0.00009), a 30% reduction in CV death (P = 0.01), and a 20% lower rate of all-cause mortality (P = 0.054), although there was a slight increase in atrial fibrillation. Sudden cardiac death and cardiac arrest were also significantly reduced by 40% and 56%, respectively. CONCLUSIONS: Patients with a history of prior MI in REDUCE-IT treated with IPE demonstrated large and significant relative and absolute risk reductions in ischemic events, including CV death. (A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. [REDUCE-IT]; NCT01492361).
引用
- Gaba, Bhatt, Steg, et al. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. J Am Coll Cardiol. 2022. PMID: 35483753. doi:10.1016/j.jacc.2022.02.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。